Who Owns NewAmsterdam Pharma N.V. Stock?
NASDAQ: NAMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 111.33%
- Institutions (% of float)
- 112.33%
- Held by insiders
- 0.89%
- Institutional holders
- 279
- Institutions 99.1%
- Insiders 0.9%
- Public and other 0.0%
Who owns NewAmsterdam Pharma N.V. stock?
Institutional investors own about 111.3% of NewAmsterdam Pharma N.V.'s shares, spread across 279 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.89% of NAMS.
The largest institutional holders are Frazier Life Sciences Management, L.P. (15.83%), Capital World Investors (10.74%) and FMR, LLC (10.10%). Together, the top 10 institutions control 71.8% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their NAMS positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of NAMS
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 18.99M | 15.83% | +5.0% |
| Capital World Investors | 12.88M | 10.74% | +5.3% |
| FMR, LLC | 12.12M | 10.10% | +17.2% |
| RA Capital Management, L.P. | 9.55M | 7.96% | 0.0% |
| Janus Henderson Group Ltd. | 8.97M | 7.48% | +297.2% |
| FCPM III Services B.V. | 8.49M | 7.08% | 0.0% |
| Deerfield Management Company, L.P | 4.25M | 3.55% | -0.3% |
| Bain Capital Life Sciences Investors, LLC | 3.81M | 3.17% | 0.0% |
| Orbis Allan Gray Ltd | 3.76M | 3.14% | +115.2% |
| Duquesne Family Office Llc | 3.36M | 2.80% | +9.3% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of NAMS
| Fund | Shares | % Held |
|---|---|---|
| SmallCap World Fund Inc | 9.56M | 7.97% |
| Fidelity Contrafund | 2.30M | 1.92% |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 2.20M | 1.84% |
| New Economy Fund | 1.25M | 1.04% |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 1.16M | 0.97% |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.02M | 0.85% |
| T. Rowe Price Health Sciences Fund, Inc. | 912.50K | 0.76% |
| Capital Group Eqy. ETF TRT I-Capital Group U.S. Small and Mid Cap ETF | 705.50K | 0.59% |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 655.54K | 0.55% |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 618.10K | 0.52% |
Frequently asked questions
Who is the largest shareholder of NewAmsterdam Pharma N.V.?
Frazier Life Sciences Management, L.P. is the largest institutional shareholder of NAMS, owning 15.83% of shares outstanding (18.99M shares) as of its latest 13F filing.
What percentage of NewAmsterdam Pharma N.V. is owned by institutions?
Institutions own about 111.3% of NAMS shares and 112.3% of the public float.
How much of NewAmsterdam Pharma N.V. do insiders own?
Insiders, such as officers and directors, own about 0.89% of NAMS shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.